Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin

Chang C

Clinical and Experimental Gastroenterology 2018, 11:335-345

Published Date: 24 September 2018